Table 2.
The range of antibacterial activity of f-hAM and c-hAM homogenates varies between multidrug-resistant strains.
| Bacterial Strain | f-hAM Homogenate | c-hAM Homogenate | ||
|---|---|---|---|---|
| 5 μL | 10 μL | 5 μL | 10 μL | |
| mean diameter of the inhibition zone ± SEM (mm) | ||||
| MRSA (reference strain) | 15.9 ± 0.5 | 18.5 ± 0.6 | 16.9 ± 0.6 | 19.6 ± 0.6 |
| MRSA (clinical strain) | 16.8 ± 0.9 | 20.1 ± 0.9 | 16.7 ± 0.9 | 20.5 ± 0.8 |
| ESBL-producing E. coli (clinical strain) | 6.4 ± 0.5 | 8.5 ± 0.6 | 5.9 ± 0.6 | 8.5 ± 0.6 |
| A. baumannii (reference strain) * | 9.6 ± 0.4 | 11.8 ± 0.4 | 8.3 ± 0.5 | 10.6 ± 0.5 |
| Carbapenem-resistant A. baumannii (clinical strain) * |
5.6 ± 0.3 | 7.4 ± 0.4 | 4.1 ± 0.6 | 5.8 ± 0.9 |
| ESBL-producing K. pneumoniae (reference strain) ** |
5.2 ± 0.3 | 7.0 ± 0.4 | 4.7 ± 0.2 | 6.3 ± 0.2 |
| ESBL-producing K. pneumoniae (clinical strain) ** |
4.7 ± 0.2 | 6.2 ± 0.3 | 4.2 ± 0.3 | 6.5 ± 0.2 |
| VRE (reference strain) | – | |||
| VRE (clinical strain) | – | |||
| P. aeruginosa (reference strain) | – | |||
| P. aeruginosa (clinical strain) | – | |||
Shown are the mean diameters ± SEM (mm) of the inhibition zones due to the antibacterial activity of f-hAM and c-hAM homogenates against the tested strains. (–) No inhibition zone. (*, **) Antibacterial activity of f-hAM and c-hAM homogenates was detected in 75% (*) or 25% (**) of all the performed tests and only these measurements were included in the mean diameter ± SEM (mm) of the inhibition zones.